Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma

Pranabashis Haldar Respiratory Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, UK Abstract: Mepolizumab (Nucala®) is an effective and specific anti-eosinophil molecular therapy that has recently been approved as add-on therapy for the management of severe eo...

Full description

Saved in:
Bibliographic Details
Main Author: Haldar P
Format: article
Language:EN
Published: Dove Medical Press 2017
Subjects:
Online Access:https://doaj.org/article/111bf5d433994f3c93b4a3dfd6b4a85f
Tags: Add Tag
No Tags, Be the first to tag this record!